ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Global, regional, and national burden of glaucoma, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to characterize the spatiotemporal trends in the global glaucoma burden from 1990 to 2023 and project future trends to 2050, informing tailored prevention and control strategies across countries.
methodsAge-standardized disability-adjusted life-year (AS-DALY) rates for glaucoma were extracted from the Global Burden of Disease Study 2023 database for 204 countries and territories. Temporal trends from 1990 to 2023 were quantified using the estimated annual percentage change (EAPC), and joinpoint regression was applied to identify significant changes in trend, with average annual percentage change (AAPC) used to summarize overall long-term patterns. Future burden from 2024 to 2050 was projected using an exponential smoothing state-space (ETS/EMS) model. Associations between burden and socio-demographic development were assessed using both Pearson and Spearman correlations with the Socio-demographic Index (SDI). An age-period-cohort framework was further used to evaluate age, period, and cohort effects on glaucoma burden.
resultsIn 2023, the global glaucoma AS-DALY rate was 7.46 per 100,000, reflecting a 39% decline (- 4.74 units) since 1990, despite a 52% rise in absolute DALYs due to population aging. Males exhibited a steeper decline (EAPC - 1.58%) than females (- 1.25%). High- and middle-SDI countries neared the minimum burden by 2000 and 2010, respectively, while low-SDI countries showed persistent high rates with partial rebounds. The period 2000-2015 accounted for 41% of the total reduction. Forecasts suggest a mean annual AS-DALY decline of 1.2% from 2023 to 2050, yielding a 27.8% reduction without rebound.
conclusionsGlaucoma exhibits a trajectory of rising cases but declining rates, with significant SDI-related disparities. Low-SDI countries require AI-enabled mass screening and access to generic medications, middle-SDI countries need risk-stratified management and laser trabeculoplasty, and high-SDI countries should focus on normal-tension glaucoma in the elderly.
Indexed as
Identifiers
42461304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.